POU3F4 Antibody

中文名稱：

POU3F4兔多克隆抗體
貨號：

CSB-PA018399LA01HU
規(guī)格：

￥440
圖片：
IHC image of CSB-PA018399LA01HU diluted at 1:200 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) POU3F4 Polyclonal antibody
Uniprot No.：

P49335
基因名：

POU3F4
別名：

Brain specific homeobox POU domain protein 4 antibody; Brain-4 antibody; Brain-specific homeobox/POU domain protein 4 antibody; BRAIN4 antibody; Brn-4 antibody; BRN4 antibody; class 3 antibody; DFN3 antibody; DFNX2 antibody; Oct-9 antibody; Octamer-binding protein 9 antibody; Octamer-binding transcription factor 9 antibody; OTF-9 antibody; OTF9 antibody; PO3F4_HUMAN antibody; POU class 3 homeobox 4 antibody; POU domain antibody; POU domain class 3 transcription factor 4 antibody; Pou3f4 antibody; transcription factor 4 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human POU domain, class 3, transcription factor 4 protein (22-134AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，POU3F4 Antibody (CSB-PA018399LA01HU)，的標(biāo)記方式是Non-conjugated。對于POU3F4 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA018399LB01HU	POU3F4 Antibody, HRP conjugated	ELISA
FITC	CSB-PA018399LC01HU	POU3F4 Antibody, FITC conjugated
Biotin	CSB-PA018399LD01HU	POU3F4 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:200-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Probable transcription factor which exert its primary action widely during early neural development and in a very limited set of neurons in the mature brain.
基因功能參考文獻(xiàn)：
1. POU3F4 mutations can be predicted by incomplete partition type III anomaly by radiological examination of the inner ear. All six of the patients showed mixed hearing loss, but none showed fluctuations in hearing, which may be related to the lack of vestibular aqueduct enlargement at the operculum. PMID: 27577114
2. Sequencing of the entire POU3F4 gene is recommended in patients with characteristic temporal bone malformations. Results of POU3F4 mutation testing are important not only for a proper genetic counseling, but also for adequate preparation and conduction of a surgical procedure. PMID: 27941975
3. A nonsense mutation is identified in a family displaying the pedigree consistent with X-linked recessive pattern in POU3F4 gene. PMID: 28051029
4. POU3F4 mutation in profoundly deaf patients may have poorer prognosis after cochlear implantation, than other types. PMID: 26600195
5. findings may greatly contribute to the elucidation of the roles of the Oct and Myc proteins in osteoblast direct reprogramming. The results may also lead to establishment of novel regenerative therapy for various bone resorption diseases PMID: 26499074
6. Audiological, medical, and family histories were collected and family members interviewed to compare hearing thresholds and case histories between cases with mutations in SMPX versus POU3F4. PMID: 24687041
7. Our data suggest that different POU3F4 mutations might show different recurrence rate in siblings of the incomplete partition type III anomaly especially in East Asian population PMID: 24608376
8. POU3F4 mutations are associated with X-linked deafness PMID: 25928534
9. We concluded that the probable presence of the third window effect is not limited to the particular type of POU3F4 mutation. PMID: 23400403
10. Results show three novel mutations in the POU3F4 gene resulting in profound hearing loss in both humans and mice. PMID: 23606368
11. Frameshift truncation and extension mutations in the C-terminus of POU3F4 lead to cytoplasmic localization and subsequent proteosomal degradation due to structural aberrations, which cause transcriptional inactivity and thus nonsyndromic hearing loss. PMID: 23076972
12. Study found no mutations in GJB6 or POU3F4 in nonsyndromic Tibetan Chinese patients with hearing impairment. PMID: 22389666
13. pou3f4 expression in inner ear might be under the control of distinct regulatory elements that fine-tune the spatio-temporal activity of this gene PMID: 21209840
14. DNA sequencing of the POU3F4 gene revealed a novel nucleotide variation, c.647G to A. The additional mutation confirms the crucial role of POU3F4 in auditory function. PMID: 21193157
15. POU3F4 did not contribute to Y linked familial deafness in a Chinese pedigree. PMID: 16229168
16. evaluation of DFN3 patients with deletions in the POU3F4 locus and detection of carrier female using MLPA. PMID: 20412083
17. novel mutations in the POU3F4 gene resulting in congenital X-linked deafness DFN3. PMID: 21250553
18. Data suggest that multiple enhancers control the expression of Pou3f4 in the inner ear and these may contribute to the phenotype observed in DFN3 patients. PMID: 20668882
19. Results strongly suggest that the deafness in DFN3 patients is largely due to the null function of POU3F4. PMID: 19671658
20. The phenotype of eight independent females carrying POU3F4 anomalies is defined, and a late-onset hearing loss is found in three patients. PMID: 19930154
21. model of DFN3 non-syndromic deafness PMID: 12062767
22. two novel mutations of the POU3F4 gene in X-linked deafness type 3 patients in the Korean population PMID: 19438930
23. This publication describes mutations in a similar mouse gene. PMID: 9667433
顯示更多

收起更多
相關(guān)疾?。?/div>
Deafness, X-linked, 2 (DFNX2)
亞細(xì)胞定位：

Nucleus.
蛋白家族：

POU transcription factor family, Class-3 subfamily
組織特異性：

Brain specific.
數(shù)據(jù)庫鏈接：

HGNC: 9217

OMIM: 300039

KEGG: hsa:5456

STRING: 9606.ENSP00000362296

UniGene: Hs.2229

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human